Pfenex Inc. and ProZyme, Inc. have entered into a joint collaboration and supply agreement in which they will develop and manufacture a range of value-added proteins which will be marketed and sold to customers in the research and diagnostics market space.

Pfenex will provide ProZyme with exclusive access to the Pfēnex Expression Technology platform for the production of an initial set of three undisclosed proteins. Pfenex will be responsible for developing production strains, fermentation process conditions and supplying bulk protein to ProZyme. ProZyme will be responsible for final product release, application support, as well as marketing and sales to customers globally. The parties will establish a joint steering committee which will oversee the development of these and future new products that will ultimately be marketed and sold by ProZyme.

“We are pleased to establish this strategic relationship with ProZyme.” said Dr. Bertrand Liang, chief executive officer of Pfenex Inc. “This agreement represents another significant milestone in the growth of our company and demonstrates once again the ability for us to leverage our Pfēnex Expression Technology platform along with our experience and infrastructure to provide commercial-scale quantities of specialty proteins. We welcome the opportunity to work with a world-class partner such as ProZyme to enable placing high-quality proteins in the hands of life science researchers. We are very impressed with ProZyme’s reputation, capabilities, sales network and deep insight into the research proteins market and look forward to growing this relationship.”